David Neil Hayes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/576158/publications.pdf

Version: 2024-02-01

183 papers 74,606 citations

75 h-index 181 g-index

191 all docs

191 docs citations

191 times ranked

84821 citing authors

#	Article	IF	CITATIONS
1	Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490, 61-70.	27.8	10,282
2	Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487, 330-337.	27.8	7,168
3	Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474, 609-615.	27.8	6,541
4	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	16.8	6,138
5	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	28.9	3,979
6	ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics, 2010, 26, 1572-1573.	4.1	3,389
7	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
8	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
9	International network of cancer genome projects. Nature, 2010, 464, 993-998.	27.8	2,114
10	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell, 2010, 17, 510-522.	16.8	2,078
11	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
12	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
13	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
14	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2017, 32, 185-203.e13.	16.8	1,428
15	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	28.9	1,417
16	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363.	9.4	1,073
17	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	27.0	1,040
18	LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007, 448, 807-810.	27.8	907

#	Article	IF	Citations
19	The chromatin accessibility landscape of primary human cancers. Science, 2018, 362, .	12.6	781
20	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
21	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
22	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell, 2017, 32, 204-220.e15.	16.8	642
23	Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus. Molecular Cell, 2004, 13, 587-597.	9.7	568
24	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
25	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
26	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
27	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
28	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483, 613-617.	27.8	430
29	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic IncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
30	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	6.4	333
31	Increasing Incidence of Oral Tongue Squamous Cell Carcinoma in Young White Women, Age 18 to 44 Years. Journal of Clinical Oncology, 2011, 29, 1488-1494.	1.6	319
32	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	6.0	318
33	Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15544-15549.	7.1	317
34	Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell, 2017, 31, 411-423.	16.8	309
35	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
36	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	16.8	270

#	Article	IF	CITATIONS
37	Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts. Journal of Clinical Oncology, 2006, 24, 5079-5090.	1.6	263
38	Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes. PLoS ONE, 2013, 8, e56823.	2. 5	263
39	Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics, 2014, 15, 419.	2.8	262
40	Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types. Clinical Cancer Research, 2010, 16, 4864-4875.	7.0	259
41	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	12.8	254
42	LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature, 2016, 539, 390-395.	27.8	248
43	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
44	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. Journal of Clinical Oncology, 2007, 25, 3978-3984.	1.6	240
45	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
46	Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation. PLoS ONE, 2012, 7, e36530.	2.5	225
47	Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data. Journal of the American Statistical Association, 2008, 103, 1281-1293.	3.1	215
48	Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination. Cancer Research, 2013, 73, 2199-2210.	0.9	209
49	Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clinical Cancer Research, 2019, 25, 4682-4690.	7.0	195
50	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. Journal of Clinical Oncology, 2013, 31, 1415-1421.	1.6	180
51	Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, 976-985.	0.8	163
52	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research, 2013, 73, 5195-5205.	0.9	153
53	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research, 2012, 18, 2056-2065.	7.0	141
54	ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics, 2014, 30, 2813-2815.	4.1	140

#	Article	IF	Citations
55	DiffSplice: the genome-wide detection of differential splicing events with RNA-seq. Nucleic Acids Research, 2013, 41, e39-e39.	14.5	138
56	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. Journal of Thoracic Oncology, 2017, 12, 943-953.	1.1	136
57	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- \hat{l}^2 Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
58	$HIF2\hat{l}\pm$ cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	8.2	129
59	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	9.4	127
60	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics, 2014, 46, 939-943.	21.4	126
61	Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. Journal of Clinical Oncology, 2015, 33, 3227-3234.	1.6	125
62	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clinical Cancer Research, 2005, 11, 565-72.	7.0	125
63	Statistical Significance for Hierarchical Clustering. Biometrics, 2017, 73, 811-821.	1.4	122
64	Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination. Cancer Research, 2014, 74, 808-817.	0.9	121
65	Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment. Head and Neck, 2007, 29, 401-411.	2.0	116
66	Association of p16 ^{INK4a} overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head and Neck, 2011, 33, 1622-1627.	2.0	109
67	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Reports, 2021, 36, 109364.	6.4	109
68	Neverâ€smokers, neverâ€drinkers: Unique clinical subgroup of young patients with head and neck squamous cell cancers. Head and Neck, 2010, 32, 499-503.	2.0	108
69	Mature results of a prospective study of deintensified chemoradiotherapy for lowâ€risk human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. Cancer, 2018, 124, 2347-2354.	4.1	107
70	Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma. PLoS ONE, 2012, 7, e34546.	2.5	104
71	BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization. Cancer Research, 2014, 74, 6486-6498.	0.9	104
72	Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer. Clinical Cancer Research, 2014, 20, 1566-1575.	7.0	99

#	Article	IF	CITATIONS
73	Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. British Journal of Cancer, 2011, 104, 545-553.	6.4	89
74	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clinical Cancer Research, 2018, 24, 5918-5924.	7.0	84
75	Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas. Cancer Discovery, 2015, 5, 239-244.	9.4	80
76	Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. Oncologist, 2018, 23, 179-185.	3.7	78
77	Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 250-257.	1.1	76
78	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Research, 2014, 42, e107-e107.	14.5	76
79	Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clinical Cancer Research, 2016, 22, 4087-4094.	7.0	75
80	Factor XIIIAâ€"expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nature Communications, 2018, 9, 1988.	12.8	69
81	Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer, 2014, 86, 255-261.	2.0	64
82	Molecular Biology of Head and Neck Cancer: Risks and Pathways. Hematology/Oncology Clinics of North America, 2008, 22, 1099-1124.	2.2	61
83	Methylation of the candidate biomarker <i>TCF21</i> is very frequent across a spectrum of earlyâ€stage nonsmall cell lung cancers. Cancer, 2011, 117, 606-617.	4.1	59
84	Role of LKB1 in lung cancer development. British Journal of Cancer, 2008, 99, 683-688.	6.4	54
85	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non–Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Archives of Pathology and Laboratory Medicine, 2013, 137, 32-40.	2.5	54
86	Head and neck carcinoma in the United States. Cancer, 2012, 118, 5783-5792.	4.1	53
87	The association between copy number aberration, DNA methylation and gene expression in tumor samples. Nucleic Acids Research, 2018, 46, 3009-3018.	14.5	51
88	High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2011, 17, 6542-6552.	7.0	49
89	TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene, 2010, 29, 1588-1597.	5.9	47
90	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25880-25890.	7.1	47

#	Article	IF	Citations
91	<i>LKB1</i> and Lung Cancer: More Than the Usual Suspects. Cancer Research, 2008, 68, 3562-3565.	0.9	45
92	Cafeteria diet-induced obesity causes oxidative damage in white adipose. Biochemical and Biophysical Research Communications, 2016, 473, 545-550.	2.1	44
93	Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. Head and Neck, 2007, 29, 497-507.	2.0	41
94	Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head and Neck, 2009, 31, 1006-1012.	2.0	40
95	Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 74-79.	1.1	40
96	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	2.5	40
97	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral Oncology, 2020, 108, 104736.	1.5	40
98	Different cellular p16INK4a localisation may signal different survival outcomes in head and neck cancer. British Journal of Cancer, 2012, 107, 482-490.	6.4	39
99	Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Reports, 2021, 35, 109285.	6.4	38
100	Phase II Trial of Hyperfractionated Intensity-Modulated Radiation Therapy and Concurrent Weekly Cisplatin for Stage III and IVa Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1081-1088.	0.8	36
101	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLoS ONE, 2015, 10, e0129280.	2.5	36
102	Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research, 2020, 26, 4260-4267.	7.0	35
103	The next steps in next-gen sequencing of cancer genomes. Journal of Clinical Investigation, 2015, 125, 462-468.	8.2	34
104	The evolving role of pemetrexed (Alimta) in lung cancer. Seminars in Oncology, 2005, 32, S16-S22.	2.2	28
105	Patterns of care in older patients with squamous cell carcinoma of the head and neck: A Surveillance, Epidemiology, and End Results-Medicare analysis. Journal of Geriatric Oncology, 2013, 4, 262-270.	1.0	27
106	Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project. Gynecologic Oncology, 2016, 142, 317-322.	1.4	27
107	Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies. Journal of Thoracic Oncology, 2008, 3, 521-526.	1.1	26
108	Concurrent Human Papillomavirus–Associated Tonsillar Carcinoma in 2 Couples. Journal of Infectious Diseases, 2009, 200, 882-887.	4.0	26

#	Article	IF	CITATIONS
109	Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies. Head and Neck, 2012, 34, 872-876.	2.0	26
110	Previous tonsillectomy modifies odds of tonsil and base of tongue cancer. British Journal of Cancer, 2016, 114, 832-838.	6.4	24
111	Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non–Small Cell Lung Carcinoma. Molecular Cancer Research, 2020, 18, 1777-1788.	3.4	24
112	Gene Silencing Associated with SWI/SNF Complex Loss during NSCLC Development. Molecular Cancer Research, 2014, 12, 560-570.	3.4	23
113	RNA Oncoimmune Phenotyping of HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas by Nodal Status. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 967.	2.2	21
114	Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncology, 2018, 84, 46-51.	1.5	21
115	Age-Within-School-Class and Adolescent Gun-carrying. Pediatrics, 1999, 103, e64-e64.	2.1	20
116	Capecitabine and lapatinib for the firstâ€line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016, 122, 2350-2355.	4.1	20
117	Autologous reconstitution of human cancer and immune system <i>in vivo</i> . Oncotarget, 2017, 8, 2053-2068.	1.8	20
118	ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data. BMC Bioinformatics, 2012, 13, 221.	2.6	19
119	BlackOPs: increasing confidence in variant detection through mappability filtering. Nucleic Acids Research, 2013, 41, e178-e178.	14.5	19
120	Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer. Cancer Research, 2016, 76, 6568-6576.	0.9	18
121	Gene Expression Subtype Predicts Nodal Metastasis and Survival in Human Papillomavirus–Negative Head and Neck Cancer. Laryngoscope, 2019, 129, 154-161.	2.0	18
122	SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. Nucleic Acids Research, 2014, 42, e113-e113.	14.5	17
123	Using the galactoseâ€Î±â€1,3â€galactose enzymeâ€linked immunosorbent assay to predict anaphylaxis in responto cetuximab. Cancer, 2016, 122, 1697-1701.	ise 4.1	17
124	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. JCO Precision Oncology, 2017, 1, 1-12.	3.0	17
125	Identification of Germline Variants in Tumor Genomic Sequencing Analysis. Journal of Molecular Diagnostics, 2018, 20, 123-125.	2.8	17
126	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens. Journal of Molecular Diagnostics, 2013, 15, 485-497.	2.8	16

#	Article	IF	CITATIONS
127	Multiclass Distance-Weighted Discrimination. Journal of Computational and Graphical Statistics, 2013, 22, 953-969.	1.7	16
128	Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 764-772.	1.2	16
129	Systematic review and metaâ€analysis of racial survival disparities among oropharyngeal cancer cases by <scp>HPV</scp> status. Head and Neck, 2020, 42, 2985-3001.	2.0	16
130	A conditional mouse expressing an activating mutation in <scp><i>NRF2</i></scp> displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue. Journal of Pathology, 2020, 252, 125-137.	4.5	16
131	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Reports, 2021, 34, 108707.	6.4	16
132	An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: Inferior outcomes for African American males in the LORHAN database. Oral Oncology, 2014, 50, 605-610.	1.5	15
133	Mutant <i>PPM1D </i> and <i>TP53 </i> Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	3.0	15
134	Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. Laryngoscope, 2012, 122, 2210-2215.	2.0	14
135	Patterns of local failure for sinonasal malignancies. Practical Radiation Oncology, 2013, 3, e113-e120.	2.1	14
136	The LKB1 Tumor Suppressor as a Biomarker in Mouse and Human Tissues. PLoS ONE, 2013, 8, e73449.	2.5	14
137	Decreased overall survival in black patients with HPV-associated oropharyngeal cancer. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102780.	1.3	14
138	Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. Expert Review of Anticancer Therapy, 2014, 14, 229-236.	2.4	13
139	Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. Cancer Medicine, 2017, 6, 397-407.	2.8	13
140	The Evolving Role of Radiotherapy for Head and Neck Cancer. Hematology/Oncology Clinics of North America, 2020, 34, 91-108.	2.2	13
141	SWISS MADE: Standardized WithIn Class Sum of Squares to Evaluate Methodologies and Dataset Elements. PLoS ONE, 2010, 5, e9905.	2.5	12
142	A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer, 2011, 71, 151-155.	2.0	12
143	ERCC1 Protein Expression Is Associated with Differential Survival in Oropharyngeal Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2013, 149, 587-595.	1.9	12
144	Concomitant Radiotherapy and Chemotherapy for High-Risk Nonmelanoma Skin Carcinomas of the Head and Neck. International Journal of Surgical Oncology, 2011, 2011, 1-8.	0.6	11

#	Article	IF	CITATIONS
145	Correlation of alterations in the <i><scp>KEAP1</scp>/<scp>CUL3</scp>/<scp>NFE2L2</scp></i> pathway with radiation failure in larynx squamous cell carcinoma. Laryngoscope Investigative Otolaryngology, 2021, 6, 699-707.	1.5	11
146	Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery. ELife, $0,11,1$	6.0	11
147	Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma. Head and Neck, 2011, 33, 1106-1114.	2.0	10
148	SCISSOR: a framework for identifying structural changes in RNA transcripts. Nature Communications, 2021, 12, 286.	12.8	10
149	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nature Communications, 2021, 12, 5945.	12.8	10
150	FiGHTS: a preliminary screening tool for adolescent firearms-carrying. Annals of Emergency Medicine, 2003, 42, 798-807.	0.6	10
151	Interpathologist Diagnostic Agreement for Non–Small Cell Lung Carcinomas Using Current and Recent Classifications. Archives of Pathology and Laboratory Medicine, 2018, 142, 1537-1548.	2.5	9
152	De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches. Practical Radiation Oncology, 2012, 2, 282-287.	2.1	8
153	Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 831-842.	7.0	8
154	Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma. Scientific Reports, 2020, 10, 9970.	3.3	7
155	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene, 2022, 41, 3423-3432.	5.9	7
156	Emerging Technologies for Improved Stratification of Cancer Patients. Cancer Journal (Sudbury, Mass) Tj ETQq0 (0 0 rgBT /0	Overlock 10 T
157	Beware of deintensification of radiation therapy in patients with p16-positive oropharynx cancer and rheumatological diseases. Practical Radiation Oncology, 2017, 7, e261-e262.	2.1	6
158	Outcomes of primary radiotherapy with or without chemotherapy for advanced oral cavity squamous cell carcinoma: Systematic review. Head and Neck, 2021, 43, 3165-3176.	2.0	6
159	Characterization of epigenomic alterations in HPV16+ head and neck squamous cell carcinomas. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.EPI-21-0922-A.2021.	2.5	6
160	The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while $TGF\hat{a}\in\hat{l}^2$ receptor plus dual checkpoint inhibition maintains antitumor immune cells. Molecular Carcinogenesis, 2022, 61, 549-557.	2.7	6
161	Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. IScience, 2022, 25, 104216.	4.1	6
162	EGFR regulation by microRNA in lung cancer: a rose by any other name … is an increasingly complicated rose. Annals of Oncology, 2008, 19, 1036-1037.	1.2	5

#	Article	IF	CITATIONS
163	MVisAGe Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors. Cancer Research, 2018, 78, 3375-3385.	0.9	5
164	Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck \hat{a} \in Mature clinical and functional outcomes. Oral Oncology, 2020, 110, 104957.	1.5	5
165	Multiple Response Regression for Gaussian Mixture Models with Known Labels. Statistical Analysis and Data Mining, 2012, 5, 493-508.	2.8	4
166	Genomic Profiling of Cancers of Unknown Primary Site. JAMA Oncology, 2015, 1, 541.	7.1	4
167	Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. Archives of Pathology and Laboratory Medicine, 2016, 140, 536-542.	2.5	4
168	$HIF2\hat{l}\pm$ cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 3182-3182.	8.2	4
169	UNMASC: tumor-only variant calling with unmatched normal controls. NAR Cancer, 2021, 3, zcab040.	3.1	4
170	The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients. Epidemiology and Health, 2021, 43, e2021035.	1.9	3
171	Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1858-1866.	2.5	3
172	Mass spectrometry in HNSCCâ€"a peek at response prediction?. Nature Reviews Clinical Oncology, 2010, 7, 193-195.	27.6	2
173	Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. Pharmacology Research and Perspectives, 2019, 7, e00519.	2.4	2
174	For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting. Journal of Clinical Oncology, 2022, 40, 1967-1970.	1.6	2
175	The Emergence of a Unique Population in Non–Small Cell Lung Cancer: Systemic or Loco-Regional Relapse Following Postoperative Adjuvant Platinum-Based Chemotherapy. Seminars in Oncology, 2006, 33, 32-38.	2.2	1
176	Matched cohort analysis of the effect of pretreatment positron emission tomography on clinical outcomes of patients with head and neck cancer treated with definitive chemoradiotherapy. Head and Neck, 2012, 34, 412-417.	2.0	1
177	Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?. Oral Oncology, 2017, 65, 125-126.	1.5	1
178	Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread. Gynecologic Oncology Reports, 2021, 36, 100720.	0.6	1
179	Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm Blood, 2009, 114, 2484-2484.	1.4	1
180	Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma. Oral Oncology, 2022, 127, 105807.	1.5	1

#	Article	IF	CITATIONS
181	In Reply to Revannasiddaiah et al: "Less intense therapy for human papilloma virus associated oropharyngeal carcinoma: Throwing caution to the wind?― Practical Radiation Oncology, 2013, 3, e97-e98.	2.1	O
182	Incidence of Nodal Disease After Nonsurgical Therapy in Head and Neck Squamous Cell Carcinoma Patients With Bilateral Neck Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 188-191.	1.3	0
183	Abstract B41: Consider the source: Normal lung expression classifies cancer histologies, subtypes, and mutations. Clinical Cancer Research, 2012, 18, B41-B41.	7.0	O